436 related articles for article (PubMed ID: 16770646)
1. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.
Vuilleumier N; Rossier MF; Chiappe A; Degoumois F; Dayer P; Mermillod B; Nicod L; Desmeules J; Hochstrasser D
Eur J Clin Pharmacol; 2006 Jun; 62(6):423-9. PubMed ID: 16770646
[TBL] [Abstract][Full Text] [Related]
2. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.
Gupta VH; Amarapurkar DN; Singh M; Sasi P; Joshi JM; Baijal R; Ramegowda PH; Amarapurkar AD; Joshi K; Wangikar PP
J Gastroenterol Hepatol; 2013 Aug; 28(8):1368-74. PubMed ID: 23875638
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis.
Cho HJ; Koh WJ; Ryu YJ; Ki CS; Nam MH; Kim JW; Lee SY
Tuberculosis (Edinb); 2007 Nov; 87(6):551-6. PubMed ID: 17950035
[TBL] [Abstract][Full Text] [Related]
4. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients.
Santos NP; Callegari-Jacques SM; Ribeiro Dos Santos AK; Silva CA; Vallinoto AC; Fernandes DC; de Carvalho DC; Santos SE; Hutz MH
Int J Tuberc Lung Dis; 2013 Apr; 17(4):499-504. PubMed ID: 23394127
[TBL] [Abstract][Full Text] [Related]
5. Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients.
Ben Fredj N; Gam R; Kerkni E; Chaabane A; Chadly Z; Boughattas N; Aouam K
Pharmacogenomics J; 2017 Jul; 17(4):372-377. PubMed ID: 27089936
[TBL] [Abstract][Full Text] [Related]
6. Association of Cytochrome P450 2E1 and N-Acetyltransferase 2 Genotypes with Serum Isoniazid Level and Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Cross-Sectional Study.
Pourmohamadi N; Pour Abdollah Toutkaboni M; Hayati Roodbari N; Tabarsi P; Baniasadi S
Iran J Med Sci; 2023 Sep; 48(5):474-483. PubMed ID: 37786472
[TBL] [Abstract][Full Text] [Related]
7. The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.
Xiang Y; Ma L; Wu W; Liu W; Li Y; Zhu X; Wang Q; Ma J; Cao M; Wang Q; Yao X; Yang L; Wubuli A; Merle C; Milligan P; Mao Y; Gu J; Xin X
PLoS One; 2014; 9(1):e85905. PubMed ID: 24465778
[TBL] [Abstract][Full Text] [Related]
8. N-acetyltransferase and cytochrome P450 2E1 gene polymorphisms and susceptibility to antituberculosis drug hepatotoxicity in an Indian population.
Mishra S; Daschakraborty S; Shukla P; Kapoor P; Aggarwal R
Natl Med J India; 2013; 26(5):260-5. PubMed ID: 25017831
[TBL] [Abstract][Full Text] [Related]
9. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients.
Sotsuka T; Sasaki Y; Hirai S; Yamagishi F; Ueno K
In Vivo; 2011; 25(5):803-12. PubMed ID: 21753138
[TBL] [Abstract][Full Text] [Related]
10. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis.
Bose PD; Sarma MP; Medhi S; Das BC; Husain SA; Kar P
J Gastroenterol Hepatol; 2011 Feb; 26(2):312-8. PubMed ID: 21261721
[TBL] [Abstract][Full Text] [Related]
11. Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity.
Singla N; Gupta D; Birbian N; Singh J
Tuberculosis (Edinb); 2014 May; 94(3):293-8. PubMed ID: 24637014
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.
Teixeira RL; Morato RG; Cabello PH; Muniz LM; Moreira Ada S; Kritski AL; Mello FC; Suffys PN; Miranda AB; Santos AR
Mem Inst Oswaldo Cruz; 2011 Sep; 106(6):716-24. PubMed ID: 22012226
[TBL] [Abstract][Full Text] [Related]
13. Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population.
Guaoua S; Ratbi I; Laarabi FZ; Elalaoui SC; Jaouad IC; Barkat A; Sefiani A
BMC Genet; 2014 Dec; 15():156. PubMed ID: 25544508
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.
Huang YS; Chern HD; Su WJ; Wu JC; Chang SC; Chiang CH; Chang FY; Lee SD
Hepatology; 2003 Apr; 37(4):924-30. PubMed ID: 12668988
[TBL] [Abstract][Full Text] [Related]
15. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis.
Lee SW; Chung LS; Huang HH; Chuang TY; Liou YH; Wu LS
Int J Tuberc Lung Dis; 2010 May; 14(5):622-6. PubMed ID: 20392357
[TBL] [Abstract][Full Text] [Related]
16. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
[TBL] [Abstract][Full Text] [Related]
17. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population.
Yamada S; Tang M; Richardson K; Halaschek-Wiener J; Chan M; Cook VJ; Fitzgerald JM; Elwood RK; Brooks-Wilson A; Marra F
Pharmacogenomics; 2009 Sep; 10(9):1433-45. PubMed ID: 19761367
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic variability of tuberculosis biomarkers in native and mestizo Peruvian populations.
Jaramillo-Valverde L; Levano KS; Tarazona DD; Capristano S; Sanchez C; Poterico JA; Tarazona-Santos E; Guio H
Pharmacol Res Perspect; 2024 Jun; 12(3):e1179. PubMed ID: 38666760
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of isoniazid-induced hepatotoxicity.
Perwitasari DA; Atthobari J; Wilffert B
Drug Metab Rev; 2015 May; 47(2):222-8. PubMed ID: 26095714
[TBL] [Abstract][Full Text] [Related]
20. Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs.
Chamorro JG; Castagnino JP; Musella RM; Nogueras M; Aranda FM; Frías A; Visca M; Aidar O; Perés S; de Larrañaga GF
J Gastroenterol Hepatol; 2013 Feb; 28(2):323-8. PubMed ID: 23190413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
